Cowen and Company’s AN2 Therapeutics ANTX Stock Holding History

Cowen and Company’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-60,278	Closed	-$908K	–	658
2022 Q1	$908K	Buy	+60,278	New	+$915K	0.09%	116

Other funds holding ANTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Cowen and Company's ANTX Position: Q2 2022 in Review

Cowen and Company sold out of AN2 Therapeutics (ANTX) in Q2 2022, closing a stake of 60,278 shares — an estimated $908K sold.

Cowen and Company first reported a position in ANTX in Q1 2022 and held it in 1 quarter. The position peaked at $908K in Q1 2022. 36 funds tracked by Wall St. Rank hold ANTX as of Q2 2022.

Cowen and Company reported no remaining AN2 Therapeutics position as of Q2 2022 after selling out during the quarter.
Cowen and Company sold 60,278 AN2 Therapeutics shares in Q2 2022, an estimated $908K.
Cowen and Company first reported a position in AN2 Therapeutics in Q1 2022 and held it in 1 quarter.
Cowen and Company's AN2 Therapeutics position peaked at $908K in Q1 2022.
36 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2022.

Based on Cowen and Company's 13F filing for Q2 2022, filed 5 Aug 2022.